Want to see NCEL full AI Analyst Report?
Top Page
NewcelX
(NASDAQ:NCEL)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.50
â–˛(31.58% Upside)
Action:N/A
Date:07/01/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and persistent negative free cash flow implying funding risk). Technicals offer only partial support with the stock above short/medium moving averages but still below the 200-day average. Valuation is also constrained by a negative P/E and no provided dividend yield.
Positive Factors
Regulatory alignment: FDA Pre-IND
A constructive Type B Pre-IND meeting with the FDA materially lowers regulatory uncertainty for NCEL-101. Favorable CMC and preclinical feedback clears key IND-enabling paths, improving the program’s ability to reach first-in-human trials and de-risk timelines that underpin long-term value creation.
Negative Factors
No revenue; sustained losses
The company reports no product revenue and persistent net losses, meaning it cannot self-fund development from operations. This structural absence of operating income imposes ongoing reliance on external capital and increases execution risk if clinical progress slows or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment: FDA Pre-IND
A constructive Type B Pre-IND meeting with the FDA materially lowers regulatory uncertainty for NCEL-101. Favorable CMC and preclinical feedback clears key IND-enabling paths, improving the program’s ability to reach first-in-human trials and de-risk timelines that underpin long-term value creation.
Read all positive factors
NewcelX (NCEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.58M
Dividend YieldN/A
Average Volume (3M)320.89K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,345,184
10 Day Avg. Volume34,320
30 Day Avg. Volume320,894
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.63
Enterprise Value/Market Cap-0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit833.27
Enterprise Value/Ebitda0.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NewcelX Business Overview & Revenue Model
Company Description
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and sm...
NewcelX Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -3.32K | -11.41K | -11.41K | -10.05K |
| EBITDA | -2.24M | -3.63M | -11.80M | -15.47M | -11.85M |
| Net Income | -8.30M | -1.98M | -12.17M | -16.50M | -11.95M |
Balance Sheet | |||||
| Total Assets | 11.45M | 2.23M | 1.85M | 9.28M | 5.76M |
| Cash, Cash Equivalents and Short-Term Investments | 2.20M | 1.67M | 897.68K | 8.95M | 5.43M |
| Total Debt | 355.00K | 0.00 | 1.63M | 0.00 | 0.00 |
| Total Liabilities | 4.20M | 826.76K | 10.68M | 6.00M | 5.22M |
| Stockholders Equity | 7.25M | 1.41M | -8.83M | 3.28M | 542.39K |
Cash Flow | |||||
| Free Cash Flow | -2.77M | -4.27M | -9.68M | -13.88M | -14.98M |
| Operating Cash Flow | -2.77M | -4.27M | -9.68M | -13.88M | -14.94M |
| Investing Cash Flow | 1.70M | -3.92K | 0.00 | -3.51M | -39.56K |
| Financing Cash Flow | 2.63M | 5.04M | 1.63M | 17.40M | 20.34M |
NewcelX Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
NewcelX Corporate Events
NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials
Jul 1, 2026
On July 1, 2026, NewcelX announced it had completed a successful Type B Pre-IND meeting with the U.S. Food and Drug Administration, securing constructive feedback and alignment on its development strategy for NCEL-101 in type 1 diabetes. The FDA&#...
NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting
Jun 30, 2026
On June 30, 2026, NewcelX Ltd. convened its Annual General Shareholders’ Meeting in Switzerland, where shareholders approved all proposals presented, each receiving at least the required majority. The approvals, aligned with items previously...
NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis
Jun 15, 2026
On June 15, 2026, Switzerland-based NewcelX announced publication of a peer-reviewed study in Stem Cell Reports highlighting AstroRx, its clinical-grade hESC-derived astrocyte therapy, as a promising treatment approach for multiple sclerosis and o...
NewcelX Calls June 30, 2026 Shareholders’ Meeting as 2025 Losses Deepen
Jun 5, 2026
NewcelX has convened its ordinary shareholders’ meeting for June 30, 2026, in Zurich, setting June 5, 2026, as the record date for investors entitled to vote. The agenda centers on routine governance items, including re-election of the indep...
NewcelX Files Pre-IND With FDA for NCEL-101 Type 1 Diabetes Cell Therapy
May 27, 2026
On May 27, 2026, NewcelX Ltd. announced it has submitted a Pre-IND briefing package to the U.S. FDA to support a proposed first-in-human clinical trial of NCEL-101 for Type 1 Diabetes, in combination with Eledon Pharmaceuticals’ investigatio...
NewcelX Posts 2025 Results and Bolsters Funding to Accelerate Type 1 Diabetes Program
Apr 30, 2026
On April 30, 2026, NewcelX reported its 2025 financial results and outlined progress on NCEL-101, its stem-cell-derived islet therapy for Type 1 diabetes, developed in collaboration with Eledon Pharmaceuticals. The company highlighted a transforma...
NewcelX Highlights Type 1 Diabetes Flagship and Eledon Collaboration in Updated April 2026 Presentation
Apr 20, 2026
On April 20, 2026, NewcelX released an updated corporate presentation and investor materials highlighting NCEL-101, its Type 1 diabetes flagship program, as the centerpiece of its development strategy. The update also reflects the company’s ...
NewcelX Raises $1.35 Million in Premium-Priced Private Placement to Advance Type 1 Diabetes Program
Apr 1, 2026
On April 1, 2026, Zurich-based NewcelX Ltd. announced it had entered into definitive securities purchase agreements for a $1.35 million private placement priced at $2.75 per share, a 30% premium to its March 31 closing price. The deal covers 490,9...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.